ArticleHepatology communications2026
B4GALT1 deficiency attenuates steatohepatitis by regulating the PPARγ/ACSL4 axis.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Divergent Trajectories of the Burden of MASLD Attributable to High Fasting Plasma Glucose in China and Globally: A GBD Study 1990-2021 and Projections to 2046.Gastroenterology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipotoxicity, driven by dysregulated lipid metabolism, is a key initiator of hepatocyte injury in metabolic dysfunction-associated steatotic liver disease (MASLD). β-1,4-galactosyltransferase 1 (B4GALT1), which primarily mediates galactosylation of glycoproteins and glycolipids, is involved in the regulation of plasma lipid composition. Previous studies have implicated aberrant glycosylation in MASLD progression. However, the role and underlying molecular mechanisms of B4GALT1 in MASLD progression remain unclear. METHODS AND
resultsThe protein levels of B4GALT1 were elevated in patients with MASLD as well as in a murine model of MASLD induced by choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD), with a more pronounced increase observed in MASH. Hepatocyte-specific B4galt1-knockout mice exhibited significantly attenuated hepatic steatosis and inflammation, but not fibrosis. In addition, hepatic B4GALT1 deficiency suppressed the expression of lipogenic genes, reduced lipid accumulation, and inhibited ferroptosis mediated by lipid peroxidation. Mechanistically, B4GALT1 deficiency impaired the N-glycosylation of peroxisome proliferator-activated receptor gamma (PPARγ), leading to its stabilization. Increased PPARγ protein, in turn, transcriptionally repressed acyl-CoA synthetase long chain family member 4 (ACSL4), thereby mitigating lipid peroxidation. Conversely, PPARγ overexpression in steatotic hepatocytes rescued the pro-ferroptotic phenotype driven by B4GALT1.
conclusionsOur findings suggest that B4GALT1 plays a crucial role in MASLD progression by targeting lipid peroxidation in hepatocytes via the PPARγ/ACSL4 axis, thus highlighting a potential therapeutic target for MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.